Brn-2 Expression Controls Melanoma Proliferation and Is Directly Regulated by β-Catenin

REFERENCES

• Behrens, J., von Kries J. P., Kuhl M., Bruhn L., Wedlich D., Grosschedl R., and Birchmeier W.. 1996. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382:638–642.
   PubMed Web of Science ®Google Scholar
• Bert, A. G., Burrows J., Hawwari A., Vadas M. A., and Cockerill P. N.. 2000. Reconstitution of T cell-specific transcription directed by composite NFAT/Oct elements. J. Immunol. 165:5646–5655.
   PubMed Web of Science ®Google Scholar
• Cadigan, K. M., and Nusse R.. 1997. Wnt signaling: a common theme in animal development. Genes Dev. 11:3286–3305.
   PubMed Web of Science ®Google Scholar
• Caelles, C., Hennemann H., and Karin M.. 1995. M-phase-specific phosphorylation of the POU transcription factor GHF-1 by a cell cycle-regulated protein kinase inhibits DNA binding. Mol. Cell. Biol. 15:6694–6701.
   PubMedGoogle Scholar
• Chin, L., Merlino G., and Depinho R. A.. 1998. Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12:3467–3481.
   PubMedGoogle Scholar
• Cohen, Y., Goldenberg-Cohen N., Parrella P., Chowers I., Merbs S. L., Pe'er J., and Sidransky D.. 2003. Lack of BRAF mutation in primary uveal melanoma. Investig. Ophthalmol. Vis. Sci. 44:2876–2878.
   PubMed Web of Science ®Google Scholar
• Cruz, F., 3rd, Rubin B. P., Wilson D., Town A., Schroeder A., Haley A., Bainbridge T., Heinrich M. C., and Corless C. L.. 2003. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 63:5761–5766.
   PubMed Web of Science ®Google Scholar
• Davies, H., Bignell G. R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M. J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B. A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G. J., Bigner D. D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J. W., Leung S. Y., Yuen S. T., Weber B. L., Seigler H. F., Darrow T. L., Paterson H., Marais R., Marshall C. J., Wooster R., Stratton M. R., and Futreal P. A.. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949–954.
   PubMed Web of Science ®Google Scholar
• Dorsky, R. I., Moon R. T., and Raible D. W.. 1998. Control of neural crest cell fate by the Wnt signalling pathway. Nature 396:370–373.
   PubMed Web of Science ®Google Scholar
• Dorsky, R. I., Raible D. W., and Moon R. T.. 2000. Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. Genes Dev. 14:158–162.
   PubMedGoogle Scholar
• Dunn, K. J., Williams B. O., Li Y., and Pavan W. J.. 2000. Neural crest-directed gene transfer demonstrates wnt1 role in melanocyte expansion and differentiation during mouse development. Proc. Natl. Acad. Sci. USA 97:10050–10055.
   PubMedGoogle Scholar
• Eastman, Q., and Grosschedl R.. 1999. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr. Opin. Cell Biol. 11:233–240.
   PubMed Web of Science ®Google Scholar
• Edmunds, S. C., Cree I. A., Di Nicolantonio F., Hungerford J. L., Hurren J. S., and Kelsell D. P.. 2003. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br. J. Cancer 88:1403–1405.
   PubMed Web of Science ®Google Scholar
• Eisen, T., Easty D. J., Bennett D. C., and Goding C. R.. 1995. The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. Oncogene 11:2157–2164.
   PubMedGoogle Scholar
• Galibert, M. D., Carreira S., and Goding C. R.. 2001. The Usf-1 transcription factor is a novel target for the stress-responsive p38 kinase and mediates UV-induced tyrosinase expression. EMBO J. 20:5022–5031.
   PubMed Web of Science ®Google Scholar
• Goding, C. R. 2000. Melanocyte development and malignant melanoma. Forum (Genoa) 10:176–187.
   PubMedGoogle Scholar
• Goding, C. R. 2000. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev. 14:1712–1728.
   PubMed Web of Science ®Google Scholar
• Goodall, J., Wellbrock C., Dexter T. J., Roberts K., Marais R., and Goding C. R.. 2004. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell. Biol. 24:2924–2932.
   Google Scholar
• Hodgkinson, C. A., Moore K. J., Nakayama A., Steingrimsson E., Copeland N. G., Jenkins N. A., and Arnheiter H.. 1993. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74:395–404.
   PubMed Web of Science ®Google Scholar
• Hou, L., Panthier J. J., and Arnheiter H.. 2000. Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage: interactions between KIT and MITF. Development 127:5379–5389.
   PubMedGoogle Scholar
• Hsu, S. C., Galceran J., and Grosschedl R.. 1998. Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with beta-catenin. Mol. Cell. Biol. 18:4807–4818.
   PubMed Web of Science ®Google Scholar
• Huber, O., Korn R., McLaughlin J., Ohsugi M., Herrmann B. G., and Kemler R.. 1996. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech. Dev. 59:3–10.
   PubMed Web of Science ®Google Scholar
• Hughes, M. J., Lingrel J. B., Krakowsky J. M., and Anderson K. P.. 1993. A helix-loop-helix transcription factor-like gene is located at the mi locus. J. Biol. Chem. 268:20687–20690.
   PubMed Web of Science ®Google Scholar
• Ikeya, M., Lee S. M. K., Johnson J. E., McMahon A. P., and Takada S.. 1997. Wnt signalling required for expansion of neural crest and CNS progenitors. Nature 289:966–970.
   Google Scholar
• Kioussi, C., Briata P., Baek S. H., Rose D. W., Hamblet N. S., Herman T., Ohgi K. A., Lin C., Glieberman A., Wang J., Brault V., Ruiz-Lozano P., Nguyen H. D., kemler R., Glass C. K., Wynshaw-Boris, and Rosenfeld M. G.. 2002. Identification of a Wnt/Dvl/β-catenin>Pitx1 pathway mediating cell-type-specific proliferation during development. Cell 111:673–685.
   PubMed Web of Science ®Google Scholar
• Leonard, J. H., and Bell J. R.. 1997. Insights into the Merkel cell phenotype from Merkel cell carcinoma cell lines. Aust. J. Dermatol. 38(Suppl. 1):S91–S98.
   Google Scholar
• Lowings, P., Yavuzer U., and Goding C. R.. 1992. Positive and negative elements regulate a melanocyte-specific promoter. Mol. Cell. Biol. 12:3653–3662.
   PubMedGoogle Scholar
• Mackenzie, M. A., Jordan S. A., Budd P. S., and Jackson I. J.. 1997. Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo. Dev. Biol. 192:99–107.
   PubMed Web of Science ®Google Scholar
• Molenaar, M., van de Wetering M., Oosterwegel M., Peterson-Maduro J., Godsave S., Korinek V., Roose J., Destree O., and Clevers H.. 1996. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 86:391–399.
   PubMed Web of Science ®Google Scholar
• Murakami, T., Toda S., Fujimoto M., Ohtsuki M., Byers H. R., Etoh T., and Nakagawa H.. 2001. Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem. Biophys. Res. Commun. 288:8–15.
   PubMedGoogle Scholar
• Nakai, S., Kawano H., Yudate T., Nishi M., Kuno J., Nagate A., Jishage K.-i., Hamada H., Fujii H., Kawamura K., Shiba K., and Noda T.. 1995. The POU domain trnscription factor Brn-2 is required for the determination of specific neuronal linages in the hypothalamus of the mouse. Genes Dev. 9:3109–3121.
   PubMedGoogle Scholar
• Pollock, P. M., Harper U. L., Hansen K. S., Yudt L. M., Stark M., Robbins C. M., Moses T. Y., Hostetter G., Wagner U., Kakareka J., Salem G., Pohida T., Heenan P., Duray P., Kallioniemi O., Hayward N. K., Trent J. M., and Meltzer P. S.. 2003. High frequency of BRAF mutations in nevi. Nat. Genet. 33:19–20.
   PubMed Web of Science ®Google Scholar
• Rigel, D. S., Friedman R. J., and Kopf A. W.. 1996. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J. Am. Acad. Dermatol. 34:839–847.
   PubMed Web of Science ®Google Scholar
• Rimm, D. L., Caca K., Hu G., Harrison F. B., and Fearon E. R.. 1999. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol. 154:325–329.
   PubMed Web of Science ®Google Scholar
• Rimoldi, D., Salvi S., Lienard D., Lejeune F. J., Speiser D., Zografos L., and Cerottini J. C.. 2003. Lack of BRAF mutations in uveal melanoma. Cancer Res. 63:5712–5715.
   PubMed Web of Science ®Google Scholar
• Rubinfeld, B., Robbins P., El-Gamil M., Albert I., Porfiri E., and Polakis P.. 1997. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790–1792.
   PubMed Web of Science ®Google Scholar
• Schonemann, M. D., Ryan A. K., McEvilly R. J., O'Connell S. M., Arias C. A., Kalla K. A., Li P., Sawchenko P. E., and Rosenfeld M. G.. 1995. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev. 9:3122–3155.
   PubMedGoogle Scholar
• Schreiber, E., Harshman K., Kemler I., Malipiero U., Schaffner W., and Fontana A.. 1990. Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. Nucleic Acids Res. 18:5495–5503.
   PubMedGoogle Scholar
• Schreiber, E., Himmelmann A., Malpiero U., Tobler A., Stahel R., and Fontana A.. 1992. Human small cell lung cancer expresses the octamer DNA-binding and nervous system-specific transcription factor N-Oct 3 (Brain-2). Cancer Res. 52:6121–6124.
   PubMedGoogle Scholar
• Schreiber, E., Merchant R. E., Wiestler O. D., and Fontana A.. 1994. Primary brain tumors differ in their expression of octamer deoxyribonucleic acid-binding transcription factors from long-term cultured glioma cell lines. Neurosurgery 34:129–135.
   PubMedGoogle Scholar
• Segil, N., Roberts B., and Heintz N.. 1991. Mitotic phosphorylation of the Oct-1 homeodomain and regulation of Oct-1 DNA binding activity. Science 254:1814–1816.
   PubMedGoogle Scholar
• Smit, D. J., Smith A. G., Parsons P. G., Muscat G. E., and Sturm R. A.. 2000. Domains of Brn-2 that mediate homodimerization and interaction with general and melanocytic transcription factors. Eur. J. Biochem. 267:6413–6422.
   PubMedGoogle Scholar
• Takeda, K., Yasumoto K., Takada R., Takada S., Watanabe K., Udono T., Saito H., Takahashi K., and Shibahara S.. 2000. Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J. Biol. Chem. 275:14013–14016.
   PubMed Web of Science ®Google Scholar
• Tetsu, O., and McCormick F.. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–426.
   PubMed Web of Science ®Google Scholar
• Thomson, J. A., Murphy K., Baker E., Sutherland G. R., Parsons P. G., and Sturm R. A.. 1995. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene 11:690–700.
   Google Scholar
• van de Weterring, M., Sancho E., Verwij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., and Hramis A.-P.. 2002. The β-catenin/Tcf-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111:241–250.
   PubMedGoogle Scholar
• Verma, U. N., Surabhi R. M., Schmaltieg A., Becerra C., and Gaynor R. B.. 2003. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9:1291–1300.
   PubMed Web of Science ®Google Scholar
• Wehrle-Haller, B., Meller M., and Weston J. A.. 2001. Analysis of melanocyte precursors in Nf1 mutants reveals that MGF/KIT signaling promotes directed cell migration independent of its function in cell survival. Dev. Biol. 232:471–483.
   PubMed Web of Science ®Google Scholar
• Widlund, H. R., Horstmann M. A., Price E. R., Cui J., Lessnick S. L., Wu M., He X., and Fisher D. E.. 2002. β-Catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J. Cell Biol. 158:1079–1087.
   PubMedGoogle Scholar
• Wiebe, M. S., Nowling T. K., and Rizzino A.. 2003. Identification of novel domains within Sox-2 and Sox-11 involved in autoinhibition of DNA binding and partnership specificity. J. Biol. Chem. 278:17901–17911.
   PubMed Web of Science ®Google Scholar
• Yavuzer, U., and Goding C. R.. 1994. Melanocyte-specific gene expression: role of repression and identification of a melanocyte-specific factor, MSF. Mol. Cell. Biol. 14:3494–3503.
   PubMedGoogle Scholar